URL copied
Covid-19 vaccine has better immune response with two full-dose regime, claims Oxford
Oxford University on Thursday said that its COVID-19 vaccine candidate has a better immune response when a two full-dose regime is used rather than a full-dose followed by a half-dose booster, Reuters reported. Oxford s vaccine candidate, licensed to AstraZeneca, has published interim late stage trial results showing higher efficacy when a half dose is followed by a full dose, compared to a two full-dose regime, though more work needs to be done to affirm the result.
On Thursday, details from the Phase I/II clinical trials were released, which made no reference to the half-dose/full-dose regime, that Oxford has said had been unplanned but approved by regulators. The university said it had explored two dosing regimes in early stage trials, a full-dose/full-dose regime and a full-dose/half-dose regime, investigated as a possible dose sparing strategy.
MyLogistics training 500 SpiceXpress employees on cold chain vaccine handling
Pfizer, Bharat Biotech and Serum Institute have currently applied with the Drugs Controller General of India (DCGI) for emergency authorization of their vaccines.
Share Via Email
| A+A A- By PTI
NEW DELHI: MyLogistics Gurukul is giving online training to more than 500 employees of SpiceJet s cargo arm SpiceXpress on cold chain vaccine handling, a press release said on Monday.
The Delhi-based training academy stated in the release that it is providing online training over 2 days, 4 hours daily per batch of about 25 participants .
Pfizer, Bharat Biotech and Serum Institute have currently applied with the Drugs Controller General of India (DCGI) for emergency authorisation of their COVID-19 vaccines in the country.
Oxford-AstraZeneca s COVID vaccine can be available in 1st half of next year: Official
More importantly, this vaccine can be stored, transported and handled at comfortable refrigerated conditions (2 to 8 degrees) which is very comfortable to handle, meaning it can be administered very rapidly across the country, Singh added. PTI
Source: Reuters
Oxford-AstraZeneca s COVID-19 vaccine can be available in the country as early as the first half of next year, AstraZeneca Country President Gagandeep Singh said on Saturday. Speaking at the 93rd annual convention of industry chamber FICCI, he said that in the current pandemic the vaccine has to be made available broadly, equitably as well as in a timely manner.
Speaking at the 93rd annual convention of industry chamber FICCI, he said that in the current pandemic the vaccine has to be made available broadly, equitably as well as in a timely manner. Pune-based Serum Institute of India is conducting clinical trials of Oxford University-AstraZeneca s COVID-19 vaccine candidate Covishield in India. “We started working in April with Oxford University and currently we are hoping to get emergency use authorisation approved and that can potentially mean that we could have something which is available as early as the first half of 2021,” Singh said. In order to make the vaccine available in a time manner the entity has signed close to 3 billion dosages supply agreements across the world encompassing close to 160 countries, he noted.
Oxford-AstraZeneca s Covid-19 vaccine can be available in first half of next year: Official deccanherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from deccanherald.com Daily Mail and Mail on Sunday newspapers.